DescriptionSources: http://www.drugbank.ca/drugs/DB06825Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020715s024,021288s021,022437s002lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB06825
Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020715s024,021288s021,022437s002lbl.pdf
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It works by decreasing the production of certain hormones, which reduces testosterone levels in the body. Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone. Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1855 Sources: http://www.drugbank.ca/drugs/DB06825 |
0.3 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | TRELSTAR Approved UseIndicated for the palliative treatment of advanced prostate cancer. Launch Date9.609408E11 |
Sample Use Guides
Administered as a single intramuscular injection in either
buttock. Due to different release characteristics, the dosage strengths are not additive and must be selected based upon the desired dosing schedule.
• 3.75 mg every 4 weeks.
• 11.25 mg every 12 weeks
• 22.5 mg every 24 weeks
Route of Administration:
Intramuscular
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Jun 26 11:43:45 UTC 2021
by
admin
on
Sat Jun 26 11:43:45 UTC 2021
|
| Protein Sub Type | |
| Record UNII |
43OFW291R9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1910
Created by
admin on Sat Jun 26 11:43:45 UTC 2021 , Edited by admin on Sat Jun 26 11:43:45 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
M11194
Created by
admin on Sat Jun 26 11:43:45 UTC 2021 , Edited by admin on Sat Jun 26 11:43:45 UTC 2021
|
PRIMARY | Merck Index | ||
|
236538
Created by
admin on Sat Jun 26 11:43:45 UTC 2021 , Edited by admin on Sat Jun 26 11:43:45 UTC 2021
|
PRIMARY | RxNorm | ||
|
43OFW291R9
Created by
admin on Sat Jun 26 11:43:45 UTC 2021 , Edited by admin on Sat Jun 26 11:43:45 UTC 2021
|
PRIMARY | |||
|
SUB04985MIG
Created by
admin on Sat Jun 26 11:43:45 UTC 2021 , Edited by admin on Sat Jun 26 11:43:45 UTC 2021
|
PRIMARY | |||
|
25080282
Created by
admin on Sat Jun 26 11:43:45 UTC 2021 , Edited by admin on Sat Jun 26 11:43:45 UTC 2021
|
PRIMARY | |||
|
1696131
Created by
admin on Sat Jun 26 11:43:45 UTC 2021 , Edited by admin on Sat Jun 26 11:43:45 UTC 2021
|
PRIMARY | USP-RS | ||
|
C128693
Created by
admin on Sat Jun 26 11:43:45 UTC 2021 , Edited by admin on Sat Jun 26 11:43:45 UTC 2021
|
PRIMARY | |||
|
140194-24-7
Created by
admin on Sat Jun 26 11:43:45 UTC 2021 , Edited by admin on Sat Jun 26 11:43:45 UTC 2021
|
PRIMARY | |||
|
DBSALT001171
Created by
admin on Sat Jun 26 11:43:45 UTC 2021 , Edited by admin on Sat Jun 26 11:43:45 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
STARTING MATERIAL -> INGREDIENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:SEQUENCE(CALCULATED) | CHEMICAL |
|